Overview
Laminopathy type Decaudain-Vigouroux is an extremely rare genetic condition that was previously classified under the broader group of laminopathies — diseases caused by problems in the lamin proteins that help form the structural framework of cell nuclei. This particular subtype was named after the researchers Decaudain and Vigouroux who described it. It is now listed as an obsolete entry in the Orphanet rare disease database, meaning it has been reclassified or merged into another disease category. Laminopathies as a group can affect many body systems, including muscles, the heart, fat tissue distribution, nerves, and bones. Symptoms can vary widely depending on the specific type but often include features of lipodystrophy (abnormal distribution of body fat), insulin resistance, metabolic problems such as diabetes and high triglycerides, and sometimes muscle weakness or heart problems. Because this specific subtype is obsolete, patients who were previously given this diagnosis should work with their genetics team to determine the current, updated classification of their condition. Treatment for laminopathies is generally supportive and focused on managing individual symptoms such as metabolic complications and cardiac issues.
Key symptoms:
Abnormal distribution of body fat (lipodystrophy)Insulin resistance or diabetesHigh triglyceride levelsMuscle weaknessHeart problems such as cardiomyopathyAbnormal heart rhythmsMetabolic syndrome featuresFatty liver diseasePremature aging features in some casesJoint stiffness or contractures
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
2 eventsAssistance Publique - Hôpitaux de Paris — NA
Amryt Pharma — PHASE3
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Laminopathy type Decaudain-Vigouroux.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Laminopathy type Decaudain-Vigouroux.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Laminopathy type Decaudain-Vigouroux.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Laminopathy type Decaudain-Vigouroux.
Start the conversation →Latest news about OBSOLETE: Laminopathy type Decaudain-Vigouroux
1 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Since this diagnosis is now considered obsolete, what is the current classification of my condition?,What specific LMNA mutation do I have, and what does it mean for my health?,How often should I have cardiac screening, and what tests are needed?,What metabolic complications should I watch for, and how will they be managed?,Am I a candidate for metreleptin (Myalept) therapy?,Should my family members be tested for this genetic change?,Are there any clinical trials or new treatments being studied for my condition?
Common questions about OBSOLETE: Laminopathy type Decaudain-Vigouroux
What is OBSOLETE: Laminopathy type Decaudain-Vigouroux?
Laminopathy type Decaudain-Vigouroux is an extremely rare genetic condition that was previously classified under the broader group of laminopathies — diseases caused by problems in the lamin proteins that help form the structural framework of cell nuclei. This particular subtype was named after the researchers Decaudain and Vigouroux who described it. It is now listed as an obsolete entry in the Orphanet rare disease database, meaning it has been reclassified or merged into another disease category. Laminopathies as a group can affect many body systems, including muscles, the heart, fat tissue
How is OBSOLETE: Laminopathy type Decaudain-Vigouroux inherited?
OBSOLETE: Laminopathy type Decaudain-Vigouroux follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Are there clinical trials for OBSOLETE: Laminopathy type Decaudain-Vigouroux?
Yes — 1 recruiting clinical trial is currently listed for OBSOLETE: Laminopathy type Decaudain-Vigouroux on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.